Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Launched by INCYTE CORPORATION · Jun 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called ruxolitinib cream to see how well it works when used at its maximum amount by adults and teenagers who have a skin condition called hidradenitis suppurativa (HS). HS causes painful lumps and inflammation in certain areas of the body, and this study aims to understand if this cream can help manage those symptoms when applied to a larger area of the skin.

People who might be able to join this study are those who have had HS for at least six months, with noticeable symptoms in at least three different areas of their body and with a significant portion of their skin affected (more than 20% of their body surface). Participants should be willing to avoid using antibiotics for their HS during the study and agree to follow pregnancy-related safety precautions. During the study, participants will apply the cream as directed, and the researchers will closely monitor their skin and overall health to see how safe and effective the treatment is. It’s important to know that the study has not started recruiting yet, and certain health conditions or lab results might prevent someone from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of HS for at least 6 months before screening visit.
• • Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
• • Total estimated treatment BSA \> 20% at screening and baseline.
• • Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
• • Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
• • Further inclusion criteria apply.
• Exclusion Criteria:
• • Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
• • Laboratory values outside of the protocol-defined ranges.
• • Further exclusion criteria apply.